Physician profile
Aida Atiq
NPI 1578768735
$4,325.80
in general payments reported to CMS, 2019-2025
29 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $135 · 2021: $269 · 2022: $642 · 2023: $811 · 2024: $643 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.08 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $842.84 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $507.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $471.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $342.05 | 2019-2024 | Veozah |
| Abbott Laboratories | $317.71 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $285.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.36 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $227.17 | 2021-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.59 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $158.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $121.30 | 2022 | |
| Merck Sharp & Dohme LLC | $88.26 | 2019-2025 | Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $66.31 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $51.20 | 2019 | |
| Amarin Pharma, INC. | $45.88 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.36 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $42.97 | 2021 | |
| Dexcom, INC. | $39.82 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $27.79 | 2019 | |
| Allergan, INC. | $21.62 | 2019 | |
| Exact Sciences Corporation | $19.35 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $17.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.74 | 2019 | |
| Shield Therapeutics INC | $15.76 | 2025 | |
| Avanir Pharmaceuticals, INC. | $15.42 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.62 | 2024 | Xifaxan |
| Redhill Biopharma INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Atiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.